ORLANDO, Fla — A new analysis of a major study of the long-term effects of bariatric surgery failed to prove a mental health benefit for this...
TOPLINE: New-onset atrial fibrillation (AF) is associated with a substantially higher risk for all-cause dementia in patients with type 2 diabetes (T2D). METHODOLOGY: Studies suggest a...
ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using...
ORLANDO, Florida — With glucagon peptide-1 receptor agonist (GLP-1 RA) drugs known to have a rapid rebound of weight gain upon discontinuation, women who stop using...
ORLANDO, Florida — The use of electronic Best Practice Advisories (BPAs) doubled the rate of patient referrals for diabetes self-management education and support (DSMES) services, new...
ORLANDO, Florida — What to prioritize first in managing early diabetes? That was the question debated on an expert panel at the American Diabetes Association (ADA)...
ORLANDO, Florida — Clinicians should keep in mind concerns about overdiagnosis of thyroid cancer when prescribing glucagon-like peptide 1 (GLP-1) drugs, as the US black box...
MONTREAL —Tirzepatide (Mounjaro, Eli Lilly), the dual gastric inhibitory polypeptide–glucagon-like peptide 1 (GIP–GLP-1) receptor agonist that has shown significant benefits in diabetes and obesity, may also...
ORLANDO, Fla. — The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) reduced cardiovascular events and reduced the risk of progression to diabetes by 73%...
ORLANDO, Fla. — Patients with type 1 and 2 diabetes who delay treatment with recommended statin therapy to address the well-known high risk for cardiovascular (CV)...
It seems intuitive that because people with type 2 diabetes (T2D) generally need to avoid sugar, clinicians should recommend eating foods and using recipes containing artificial...
TOPLINE: Bariatric metabolic surgery (BMS) offers a survival advantage over glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in adults with obesity and diabetes for ≤ 10...